of pioneering transplants

BAYLOR ANNETTE C. AND HAROLD C. SIMMONS TRANSPLANT INSTITUTE ANNUAL REPORT

YEARS1984 – Fir st Baylor Transplant Team

Transplant surgeons Giuliano Testa, MD and Peter Kim, MD, on the medical

staff of Baylor University Medical Center, utilize the G9MD Broadcast Center to advance

surgical techniques and collaborate with physicians worldwide. The use of advanced

streaming technology is at the forefront of medical innovation.

1

What has kept Baylor Annette C. and Harold C. Simmons Transplant Institute at the

forefront of transplantation for 30 years? As one of the first to successfully treat organ

failure with transplants, we certainly had a vision of the potential lifesaving power

of transplant medicine. But we also had an instinctive awareness of the collaboration

at the heart of our field.

Transplantation is a science of relationships: the relationship that ties a donor to a recipient, a patient

to a team of specialists, and a referring physician to a transplant center. In every aspect of the care

we provide, we are committed to making these relationships work. With 30 years of advances in

transplantation behind us, we continue to pioneer methods to match patients with the treatment or

organ that ensures a successful outcome. We continue building trusted relationships with referring

physicians, keeping them involved in their patients’ care. And we continue forging a permanent bond

with the patients we treat, offering them a lifetime of care.

Our multi-specialty teams of renowned physicians and scientists care for thousands of patients before,

during and after transplantation, even finding effective alternative treatments for those who may not

be transplant candidates. As we have done for 30 years, we will carry on with the research, innovation

and patient-focused care that are essential to the future of transplant medicine. We consider it a

privilege to collaborate with referring physicians as we dedicate ourselves to transplant patients for life.

Sincerely,

The best way to predict the future is to invent it.

Göran Klintmalm, MD, PhD, FACS Chairman and Chief Baylor Annette C. and Harold C. Simmons Transplant Institute

Janice Whitmire, MBA Vice President Baylor Annette C. and Harold C. Simmons Transplant Institute

LEADERSHIP LETTER

Fir st Transplant Surgery

1

3

4

8

12

16

20

24

26

28

30

34

36

LEADERSHIP LETTER

INTRODUCTION

LIVER

KIDNEY & PANCREAS

ISLET CELL

HEART

LUNG

RESEARCH

OUTREACH

DONOR COMMUNITY

PUBLICATIONS

MEDICAL STAFF

BAYLOR FIRSTS

Dr. Starzl, Godfather of Trans

plantation

The original transplant pioneer,

Dr. Thomas Starzl was the inspiration

behind Baylor’s transplantation

program. Dr. Starzl performed the

first human liver transplants. In 1983,

he made a presentation to Baylor on

his transplant team’s successes at the

University of Pittsburgh. He encouraged

Baylor to develop a transplant center,

recruited his student Dr. Göran

Klintmalm as medical director, and

brought his patient Amie Garrison

to Dallas, where she made history

as Baylor’s first transplant patient.

3

Daring to embrace progressIt takes courage to perform a liver transplant on a five-year-

old girl dying of liver failure. It’s especially courageous if

that procedure is the hospital’s first transplant. But that is

what happened in 1984 at Baylor Annette C. and Harold C.

Simmons Transplant Institute. The transplant program was

still in the planning stages, but little Amie Garrison would

die without a new liver, and the nation’s only existing liver

transplant center in Pittsburg simply didn’t have room.

So Baylor said yes. Today, Amie is a healthy 35-year-old

mother. And the transplant team that took a gutsy move to

save a child’s life is now one of the largest and most renowned

multi-specialty transplant centers in the country.

For 30 years, the courage it took to perform Amie’s surgery

has defined the Baylor Annette C. and Harold C. Simmons

Transplant Institute, which includes the transplant services

of Baylor University Medical Center at Dallas and Baylor

All Saints Medical Center at Fort Worth. From day one,

we have made historic progress in each area of specialization.

Our liver transplant program is internationally recognized as

a pioneering program in liver transplantation and anti-rejection

treatment as well as hepatitis B and C research. In addition,

our living donor liver program is among the top 10 in the

nation and one of only two programs in Texas.

In our kidney transplant program, one-year survival rates

exceed the national average, and living donors are involved

in one-fourth of all kidney transplants, which addresses

a critical global shortage of donated organs.

With one of the world’s largest islet cell transplant programs,

we continue to make inroads in both allo-islet cell and auto

islet cell transplantation, providing hope for patients with type

1 diabetes and chronic pancreatitis.

In our heart transplantation program, the busiest in Texas and

the second largest in the nation, we have shortened the median

wait time for a heart transplant to as little as seven days.

In 2014, our lung transplant program welcomed a new team

of nationally respected transplant specialists and is growing

rapidly in volume and outcomes.

Clearly, our work at Baylor Annette C. and Harold C.

Simmons Transplant Institute is inspired by a bold vision of

our role in transplant medicine. Three decades of progress have

shown the value of our approach. In moving transplantation

forward, we are restoring countless lives. All the more reason

that, like the little girl we saved 30 years ago, we look forward

to a promising future.

FrenchieHEART TRANSPLANTAT AGE 61

Just five months post-transplant, Carson

“Frenchie” Cheramie was able to welcome

his namesake granddaughter, Carson

Claire, into the world. “I never imagined

that I would ever be able to hold a

grandchild, but God had a different plan.”

2014JA

N

INTRODUCTION

4

LIVER

Cred

it: S

cieP

ro /

Sci

ence

Sou

rce

5

Living Donor Transplantation

One therapeutic option is a living donor liver transplant.

The procedure allows patients to receive a liver transplant

sooner—patients who likely would die without it, faced

with long waits on the transplant list.

In a living donor transplant, the entire diseased liver is

removed from the recipient and replaced with half of the

donor’s liver. In roughly a month, both donor and recipient

livers grow to near-full volume. Because the donated liver

is immediately transplanted without needing storage or

transporting, it provides the best quality liver. The technically

demanding surgery must be performed by surgeons

experienced in the procedure. Baylor University Medical

Center is one of only two centers in Texas offering it and

one of the top 10 in the nation for volumes.

Elastography: Non-invasive Liver Disease Management

Thanks to new technology at Baylor University Medical

Center, some liver disease patients no longer have to endure

frequent liver needle biopsies to determine the progression of

their disease. A recent study at the Mayo Clinic, co-authored

by Sumeet Asrani, MD, a hepatologist now on the medical

staff at Baylor Dallas, showed that magnetic resonance

elastography can measure and stage liver disease non-

invasively. The technology allows hepatologists to determine

whether patients are getting better or worse, and whether

treatment is effective. This advanced imaging modality gives

physicians more information to better care for patents.

Soon to be FDA approved, it is available at only a few

medical centers nationwide, Baylor among them.

More liver transplants are performed at Baylor University Medical Center and Baylor All Saints combined than anywhere else in Texas. With this level of expertise, provided by one of the nation’s largest transplant surgery teams, our center offers patients a full slate of treatment options.

110

150

120

90

60

30

0

Liver Transplant Volumes BUMC & BAS

120

99

112

96

20142010 2011 2012 2013

94.6%100

80

60

40

20

0

Liver Transplant Outcomes percent alive at one year

92.9%

20142010 2011 2012 2013

US Nat’l Avg: 88.26%(SRTR Dec 2014)

92.9%

81.7% 80.2%

LIVER TRANSPLANTS* SINCE INCEPTION3,841

*Data is through Dec 2014

LIVER

6

Except for being a mail carrier, Gilbert Gonzales didn’t exercise much. But a new liver changed that. Now he travels the globe

competing in the Transplant Games of America and the World Transplant Games. In 2009 his liver was failing due to a genetic

disease. Nine months later a liver transplant at Baylor Dallas kick-started his new life. He soon jumped into the transplant

games fearlessly, winning a bronze medal in discus at his first event in Grand Rapids, Michigan, and silver medals for discus

and high jump a year later in Durban, South Africa. Most recently, in Houston, Texas, Gilbert took home silver in discus and

bronze in long jump. Gilbert volunteers in Baylor’s Better Livers program, reassuring transplant patients that their lives will

get better. “It’s all about enjoying your second life and passing it along,” he says.

GILBERT GONZALES | Age 63 | Liver Transplant

MEETGILB

ER

T

7

Liver and Pancreas Disease Center

At the Liver and Pancreas Disease Center, patients with

liver tumors, including those with potentially cancerous

liver lesions, and patients with pancreas tumors or chronic

pancreatitis have access to a full spectrum of treatment

options. One of the few centers in the nation dedicated to

treating patients with liver and pancreas cancer, the center

coordinates each patient’s tumor management and plan

of care among specialists on the medical staff, many having

more than 15 years of experience with such diseases.

Since the program’s inception in 1998, more than 5,000

patients have received treatment.

Antibody-Mediated Rejection Symposium

In March 2013, Simmons Transplant Institute held the

first scientific conference to exchange information about

antibody-mediated rejection (AMR) in liver transplantation.

Assembling more than 165 liver transplant leaders, the

symposium confirmed the role of AMR in allograft survival.

A subsequent summary of the conference was published

in the March 2014 issue of the American Journal of

Transplantation and was authored by 16 attending

world-recognized specialists. Baylor’s leadership in the

AMR findings came as a result of data mined from our

transplant biorepository of donor and recipient tissue

samples, which is the world’s largest.

Clinical Studies

For patients with hepatocellular carcinoma (HCC),

liver transplant often offers the best potential outcome.

However, in some cases, the cancer may reoccur. Baylor’s

study on the Safety and Efficacy of Everolimus Treatment

in Liver Transplantation for Liver Cancer is investigating

the medication’s ability to reduce recurrent HCC in post-

transplant patients. The study is the focus of an upcoming

mTOR Conference in Dallas.

Hepatologists on the medical staff of Baylor Dallas, as

a part of the North American Consortium for the Study

of End-stage Liver Disease, are participating in studies

investigating risk factors for mortality in decompensated liver

patients (otherwise known as acute-on-chronic liver failure)

in an effort to enhance clinical practices that will ultimately

improve patient outcomes. This study is being conducted at

Baylor Dallas, Mayo Clinic, University of Pennsylvania and

Virginia Commonwealth University.

RubenLIVING DONOR LIVER TRANSPLANT AT AGE 56

Ruben Castillo had liver failure from

Hepatitis C he contracted from a blood

transfusion. After waiting over a year

for a donor, Ruben and his wife Tammy

decided the Living Donor program was the

best option. It was a chance for Tammy to

donate to Ruben and offer him a second

chance at life. Now Ruben is

flourishing and better than ever.

2013JU

N

LIVER TRANSPLANT PROGRAM IN THE SOUTHWEST1ST

LIVER

8

KIDNEY& PANCREAS

Cred

it: S

cieP

ro /

Sci

ence

Sou

rce

9

In fact, the ideal situation is for patients to avoid

dialysis altogether and go straight to kidney transplant.

This option— a preemptive kidney transplant— requires

a living donor. We offer this advanced solution to help

patients receive a kidney as soon as possible, because

the less time spent on dialysis the better. The advantages

of a preemptive kidney transplant with a living donor

are compelling.

Patients with living donor kidney transplants have much

better survival rates and three times the life expectancy

compared to patients staying on dialysis. Without having

to wait for a deceased donor organ, they can receive their

kidneys faster. And the kidney itself is higher quality.

It starts working sooner and can last twice as long as

a deceased donor kidney. Overall, a patient’s outcome

and quality of life are far superior.

Pathway to Kidney Transplant

To encourage the early referral of patients for living donor

kidney transplantation, Baylor developed the Pathway to

Kidney Transplant, a patient education guide that demystifies

the transplant process for both recipients and donors and

explains the benefits of the living donor kidney option.

The Pathway provides a step-by-step graphic simplifying each

phase of a patient’s treatment options and drives home the

point that the sooner patients receive a kidney, the better.

Desensitization Program

Dr. Bernard Fishbach, medical director of the Kidney

Transplant Program, is leading the desensitization program.

This very active program, which removes harmful antibodies

from the blood stream and reduces the risk of organ

rejection, is available at only a few transplant centers

in the United States.

Kidney failure patients face two choices: try to live with dialysis or receive a kidney transplant. Research has shown that a kidney transplant should be first choice.

Kidney PathwayThis pathway includes checklists for patients with kidney

disease and potential donors to help guide them through the

steps to receive a kidney transplant as soon as possible.

Ideally, patients can be transplanted before starting dialysis,

which will likely improve their clinical outcome and quality

of life. The graph and checklist provide recommendations

to patients once their kidney function deteriorates to 30

percent to begin the educational, financial, physical and

potential donor candidate considerations early in order to

be ready for transplant by the time their kidneys reach 20

percent of function.

KIDNEYFUNCTION

30%

KIDNEYFUNFUNCTICTIONON

3333000%%

KIDNEYFUNCTION

20%

KIDNEYFUNCTION

220%

KIDNEYFUNCTION10-15%

KIDNEYFUNFUNCTICTIONON111000-111555%%

PATIENTWITH

KIDNEYDISEASE

PATH 1

NOTE: It’s never too late to choose Path 2.

*Refer to applicable checklists

GETREADY

FORDIALYSIS

IDENTIFYPOTENTIAL

DONORS

DIALYSIS

KIDNEYTRANSPLANT

PATH 2

GET READYTO BE AKIDNEY DONOR*

EVALUATIONTO BE AKIDNEY DONOR*

GET READYFOR KIDNEY

TRANSPLANT*

EVALUATIONFOR KIDNEY

TRANSPLANT*

INTERESTEDDONORS

9

KIDNEY

10

JOE

L & LO

NN

IE

Joel Henderson’s father Lonnie seemed healthy and was enjoying life in his fifties despite his type 1 diabetes. But then came

the fainting spells at work, and Lonnie learned his kidneys were failing. That’s when Joel offered to donate a kidney to his

dad. “We were trying to give him a kidney before he would have to go on dialysis,” says Joel. After the transplant surgery,

Joel says he recovered quickly. As for Lonnie, his transplanted kidney started working within 30 minutes, he’s had no signs

of rejection, and his energy and stamina are fully restored. Joel says, “People say it was heroic, but I’m blessed to have the

opportunity. I’m just glad to have him around longer.”

JOEL & LONNIE HENDERSON | Ages 31 & 58 | Kidney Transplant

MEET

11

Kidney-Pancreas Transplant

For patients with type 1 diabetes, a pancreas transplant can be

the best option. Sometimes the pancreas is transplanted alone,

but more often the pancreas and kidney are transplanted

together. Patients on the Baylor kidney-pancreas transplant

list wait on average no more than 4.5 months, in sharp

contrast to other centers in the region, whose wait times range

from seven to 62 months.

In a kidney-pancreas transplant, the pancreas protects the new

kidney, allowing it to perform better and longer than a kidney

alone. Many dual transplant recipients are free of diabetes

years after their transplant. Additionally, Baylor had

a 100-percent rate of patient, kidney and pancreas survival

over the past two and a half years.

Pancreatic Cyst Evaluation

Pancreatic cysts can be benign, but 20 percent of

pancreatic cancers start with a cyst. The Pancreatic Cyst

Program provides a fast, convenient way to have pancreatic

cysts evaluated and removed, if needed. A multidisciplinary

team of gastroenterologists, radiologists, pathologists and

surgeons evaluates each patient and determines the best

course of action.

191

250

200

150

100

50

0

Kidney Transplant Volumes BUMC & BAS

199189 189 194

20142010 2011 2012 2013

97.4%100

80

60

40

20

0

Kidney Transplant Outcomes percent alive at one year

95.8%

20142010 2011 2012 2013

US Nat’l Avg: 94.7%(SRTR Dec 2014) 94.7%

91.5%94.9%

191

250

200

150

100

50

0

Kidney Transplant Volumes BUMC & BAS

199189 189 194

20142010 2011 2012 2013

97.4%100

80

60

40

20

0

Kidney Transplant Outcomes percent alive at one year

95.8%

20142010 2011 2012 2013

US Nat’l Avg: 94.7%(SRTR Dec 2014) 94.7%

91.5%94.9%

3,867KIDNEY TRANSPLANTS

SINCE INCEPTION

Dr. Bernard FishbachMedical Director of Renal and Pancreas Transplantation

KIDNEY

PANCREAS TRANSPLANTS SINCE INCEPTION255

12

ISLET CELL

13

Auto Islet Cell Transplant

Baylor is the preeminent center in the Southwest and one

of the few in the world to offer this innovative therapy.

In the procedure, the pancreas and spleen are removed, and

the patient’s islet cells are extracted. They are then infused

into the patient’s liver, where they take hold and ideally

produce insulin. Baylor researchers conducted a study to

measure the improvement in patients’ post-transplant quality

of life. The results, which showed dramatic improvement, were

presented at the International Pancreas and Islet Cell Transplant

Association in September, 2013. For patients, the results are

tangible: 70 percent are narcotic-free one year after surgery.

Allo-Islet Cell Transplantation

Pancreatic islet transplantation is still considered an

investigational procedure in the U.S. as a treatment

for type 1 diabetes. But the past decade has seen

tremendous progress, and Baylor continues to contribute

scientific knowledge. In allogenic islet transplantation,

surgeons transplant islets isolated from deceased donors

into patients with type 1 diabetes. Baylor’s clinical

experience has enabled bold research initiatives that

elevate the performance of islet cell transplantation not

only in our center, but also throughout the field.

Patients with chronic pancreatitis face a life of severe, debilitating pain and often long-term narcotic dependence. At Baylor, there’s a clinical solution that can restore their quality of life—a total pancreatectomy and autologous islet cell transplant.

ISLET CELL TRANSPLANTS PERFORMED SINCE INCEPTION

125

The Outcome: Preservation of Pancreatic Endocrine Function

Patients Followed Up Over 1 Yr (n=51)(Follow up: 23.7 +/− 2.2 mos)

HbA1c LevelsAll Patients (n=81)(Follow up: 16.7 +/− 1.7 mos)

Insulin Dependent

59%

41%

68%

32%

42%

71%HbA1c<7.0%

12%

29%17%

Achievement of Insulin Independence HbA1c <5.7% 5.7–6.4% 6.5–7.0% >7% Despite removal of their pancreas, 40 percent of patients are free of exogenous insulin and a large majority of the patients have favorable HbA1C profiles.

ISLET CELL

14

Ashlyn Bollinger learned she had chronic pancreatitis at age 17. Her condition became so bad that she had to drop out of

college after a year and a half, unable to eat or alleviate the constant, severe pain. “I did nothing but lie in bed—everything

hurt,” she says. In June 2014, Ashlyn had an auto islet cell transplant. Now she’s back to an active, busy life, free to pursue

any of her passions, from sports to dog rescue. She looks forward to going back to college and becoming a nurse. “That’s my

calling,” she says. “I want to find that patient who has chronic pancreatitis and say, ‘I know exactly what you’re going through.’”

ASHLYN BOLLINGER | Age 23 | Islet Cell Transplant

AS

HLY

N

MEET

Islet Cell Research

Recently, Baylor Research Institute was awarded a patent

from the U.S. Patent Office for a potential strategy to

improve the outcomes of islet cell transplantation for patients

with type 1 diabetes or chronic pancreatitis. Our researchers

were first to report that transplanted islet cells are subject

to severe and inflammatory reaction, which damages them.

Experimental research at Baylor showed that Withaferin A

(WA), a plant-derived compound with anti-inflammatory and

anti-oxidant properties, can inhibit the inflammatory response

and protect islet cells from damage. Until now, no compound

with such benefits has been used in islet transplantation.

12 Major Centers Offering Islet Autotransplantation

US Centers:Baylor, Dallas, TXMayo, Minneapolis, MNPittsburgh, PACincinnati, OHCity Name, SCChicago, ILCity Name, AL

Overseas Centers:Leicester, UKGeneva, SwitzerlandMilan, ItalySamsung (Seoul?), S. KoreaSendai, Japan

U.S. Centers:Dallas, TXMinneapolis, MNPittsburgh, PACincinnati, OHCharleston, SCChicago, ILBirmingham, AL

1

2

3

4

5

6

7

8

9

10

11

12

1

2

3

4

5

6

7

Leicester, UK

Seoul, S. Korea

Geneva, Switzerland

Milan, Italy

Sendai, Japan

While 93 percent of our patients are narcotic-dependent before surgery, a remarkable 71percent are narcotic-free one year after surgery.

Narcotic Dependence

Before TP-AIT

Narcotic-dependent

1 Year After TP-AIT

93%

7%

71%

29%

Narcotic-free

While 93% of our patients are narcotic-dependent before surgery, a remarkable 71% are narcotic-free one year after surgery.

IN THE NATION IN AUTO ISLET TRANSPLANT VOLUME#2

15

ISLET CELL

16

HEARTCr

edit:

Sci

ePro

/ S

cien

ce S

ourc

e

17

Since the arrival of a new surgical team in 2012, the volume

of transplants has tripled in two years. And the median wait

time for status 1A patients has shrunk to just seven days.

Our growth in volume and depth of experience have put

Baylor in an optimal philosophical position as well. We accept

high risk patients, even those that other centers have declined,

yet have maintained survival rates that exceed the national

average. We also have developed strong relationships with

other transplant centers and heart failure centers, welcoming

patients from across the nation, in some cases arranging

for patients to return to their original transplant center for

follow-up care. Patients and physicians may take advantage

of dual listing at two or more transplant centers, which can

reduce the wait time for a transplant. Further, we collaborate

with transportation companies to provide a patient’s timely

arrival for their procedure.

Leading the transplant team are Gonzalo Gonzalez-Stawinski,

MD and Shelley Hall, MD. In addition to adding surgeons

and transplant cardiologists on the medical staff in late 2014,

we are expanding our midlevel clinical staff. We’ve instituted

a cardiothoracic surgical fellowship for transplant LVAD

training and are developing a fellowship for advanced heart

failure transplant training.

Our deep commitment to referring physicians continues to

expand and strengthen our referral network. We maintain

continuous contact with referring physicians, not only

updating them on their patients’ status at every turn but also

sharing as much of their patients’ care management as they

choose. These collaborations benefit patients as well, as they

can return home for follow-up care.

Left Ventricular Assist Devices

Not all patients are candidates for a heart transplant, but an

implantable left ventricular assist device (LVAD) may be an

option for managing their advanced heart failure. In fact, the

When it comes to heart transplantation, Baylor’s role is central—literally. Our location near the center of the country puts us within just a few hours of donor hearts, expanding the treatment options for patients nationwide.

HEART TRANSPLANTS IN 2014102

102

10

20

30

40

50

60

70

80

90

100

0

Heart Transplant Volumes

2430

43

68

20142010 2011 2012 2013

94.1%100

80

60

40

20

0

Heart Transplant Outcomes percent alive at one year

20142010 2011 2012 2013

US Nat’l Avg: 90.9%(SRTR Dec 2014) 96.7%

91.7%85.3%86.1%

102

10

20

30

40

50

60

70

80

90

100

0

Heart Transplant Volumes

2430

43

68

20142010 2011 2012 2013

94.1%100

80

60

40

20

0

Heart Transplant Outcomes percent alive at one year

20142010 2011 2012 2013

US Nat’l Avg: 90.9%(SRTR Dec 2014) 96.7%

91.7%85.3%86.1%

HEART

18

Trenton Cary is on his third heart. Born with a congenital heart defect, he had a heart transplant just shy of his first birthday.

That heart served him well for the next 20 years. At college he noticed a drop in his energy and chalked it up to lack of sleep.

But one day he was running to help a friend catch his loose dog and suffered a heart attack. Doctors discovered that his heart

was being rejected. Nine hours after Trenton was put on the transplant wait list, he received a new heart. Seven months later,

Trenton says, “I can do anything I want.” With the way he takes to volleyball, soccer, baseball and martial arts, it’s clear that

what he wants is to stay active.

TRENTON CARY | Age 24 | Heart Transplant

TR

EN

TO

N

MEET

19

28

10

20

30

40

50

60

0

VAD Transplant Volumes

2723

45

40

20142010 2011 2012 2013

100

80

60

40

20

0

VAD Transplant Outcomes percent alive at one year

20142010 2011 2012 2013

INTERMACS Post Implant Survival 2013 Q4: 78.00%

82.6%81.5%

65.0%62.2% 64.3%

28

10

20

30

40

50

60

0

VAD Transplant Volumes

2723

45

40

20142010 2011 2012 2013

100

80

60

40

20

0

VAD Transplant Outcomes percent alive at one year

20142010 2011 2012 2013

INTERMACS Post Implant Survival 2013 Q4: 78.00%

82.6%81.5%

65.0%62.2% 64.3%

shortage of donor organs makes it imperative that we offer

patients access to innovative heart-assist devices. We also

practice shared care with referring physicians after patients

are released, including offering LVAD training for those who

choose to be more involved in the ongoing management

of their patients’ care.

The expansion of our transplant program and the addition

of sophisticated circulatory support devices have moved

Baylor into a position to provide more advanced care for

heart failure. For some patients who are too unstable for a

major intervention, Baylor offers extracorporeal membrane

oxygenation (ECMO). Unlike devices that support only

the left ventricle, ECMO can support both ventricles.

Often needed on an emergency basis, ECMO may be used

to stabilize a patient so that physicians can determine if a

longer-term option is appropriate. We have transported

patients with ECMO from up to 390 miles away.

Heart transplantation remains the ultimate bi-ventricle

support. Now, due to Baylor’s efficient and thorough

evaluation of patients and short median wait times, many

patients can go straight to transplant without the interim

step of an LVAD implantation. 2012 12013 52014 16

ECMO Transports By Year

Farthesttransport

with ECMO:390 miles

Transport period: Nov 2012 – May 2014

BAYLOR DALLAS IS ONE

OF ONLY TWO CENTERS

IN THE U.S. THAT PERFORM

MORE THAN 75 HEART

TRANSPLANTS A YEAR

HEART

20

LUNG

Cred

it: S

cieP

ro /

Sci

ence

Sou

rce

21

The Center for Advanced Heart and Lung Disease focuses

on more than lung transplants. We also offer a full range

of diagnostic tools and advanced therapies for patients with

complex, chronic and rare lung diseases. Patients receive

coordinated care from a multidisciplinary team of pulmonary

physician specialists, nurse practitioners, nurse coordinators,

respiratory therapists, dieticians and social workers.

Offering all diagnostic and therapeutic options in one center

is more convenient for patients. The team approach is even

more appreciated by referring physicians, who lack the time

to provide the complexity of diagnostic and therapeutic

options and education needed by these patients.

Patients with acute respiratory failure may be candidates for

circulatory support with extracorporeal membrane oxygenation

(ECMO), a therapy that Baylor also uses for patients with

heart failure. The implantable device is used primarily for

reversible lung conditions, such as pneumonia, or as a bridge

to lung transplant for patients on the waiting list.

Patients with emphysema also have access to minimally

invasive lung volume reduction surgery (LVRS). Lung volume

reduction surgery is a procedure where surgeons remove

portions of diseased lung tissue damaged by severe emphysema.

By removing poorly functioning tissue, remaining lung tissue

can work more efficiently.

Baylor Dallas also offers patients access to clinical trials

evaluating potential therapeutic agents. Currently, we are

participating in clinical trials to evaluate two new drug

For people living with lung diseases like cystic fibrosis, pulmonary fibrosis, emphysema and other conditions, every breath is a struggle. For such patients, Baylor’s lung transplant team can offer a new lease on life. The volume of transplants performed at Baylor puts our program in the top 25 percent of centers nationally.

LUNG TRANSPLANTS IN 201437

David P. Mason, MD, is the chief of thoracic surgery and lung transplantation for the Baylor Scott & White Health system. Dr. Mason is an international leader in the field of lung transplantation. Before joining Baylor Scott & White in 2014, he was on the surgical staff at Johns Hopkins University and the Cleveland Clinic in Cleveland, Ohio. He leads the department of thoracic surgery at Baylor University Medical Center at Dallas and the Center for Thoracic Surgery.

Dr. Mason has many research interests and is widely published in all areas of thoracic surgery. He is the author of numerous articles and book chapters. He is a member of multiple international societies and leadership committees, including the Joint Commission for Thoracic Surgery Education, the Thoracic Organ Committee of the American Society of Transplant Surgeons, the Interventional Chest/Diagnostic Procedures Network Steering Committee of CHEST and the International Advisory Committee of the American Association of Thoracic Surgery.

Dr. David Mason Joins Baylor Dallas’ Lung Transplant Team

LUNG

22

As if growing up with cystic fibrosis wasn’t bad enough, Carrie Giddens lost her brother to the same disease. In the fall of

2012 she was a grieving sister, a new mother of twins and plagued with frequent lung infections. After spending most of

October in the hospital, she got home in time to take her boys trick-or-treating. Two days later she was in critical care and

crashing. The transplant team put Carrie on ECMO to keep her alive and fast-tracked her for a lung transplant. Before the

month was out she had new lungs and made it home in time for Christmas. “I was their first lung transplant patient to have

ECMO,” she says. “If I’d been at any other hospital, I don’t think I would have made it.”

CARRIE GIDDENS | Age 29 | Double Lung Transplant

CA

RR

IE

MEET

23

Gene PeytonDOUBLE LUNG TRANSPLANTAT AGE 66

After receiving a double lung transplant, Reverend Gene Payton

says that overseeing his church’s food pantry—including delivering

food items and restocking shelves—is a labor of love. “I find it hard

to believe that I’m actually loving being able to work,” he says.

2012MA

Y

3740

35

30

25

20

15

10

5

0

Lung Transplant Volumes

11

29

16

29

20142010 2011 2012 2013

91.9%100

80

60

40

20

0

Lung Transplant Outcomes percent alive at one year

63.6%

93.8%89.7%

20142010 2011 2012 2013

US Nat’l Avg: 87.7%(SRTR Dec 2014)

79.3%

3740

35

30

25

20

15

10

5

0

Lung Transplant Volumes

11

29

16

29

20142010 2011 2012 2013

91.9%100

80

60

40

20

0

Lung Transplant Outcomes percent alive at one year

63.6%

93.8%89.7%

20142010 2011 2012 2013

US Nat’l Avg: 87.7%(SRTR Dec 2014)

79.3%

therapies, nintedanib and pirfenidone, for interstitial lung

disease, also known as interstitial pneumonia. Data presented

at the American Thoracic Society and published in the

New England Journal of Medicine showed positive benefits

with both drugs.

With the recent additions to our medical and surgical team,

our program has extensive experience in the surgical and

medical care of lung transplant patients. This allows our

program to accept patients with complex conditions that

other centers may refuse. In addition, we are actively involved

in research to improve outcomes after lung transplantation.

Baylor University Medical Center at Dallas is the top-ranked

hospital in North Texas and continues to be ranked as one

of America’s top hospitals by U.S. News & World Report.

Our experienced lung transplant team at Baylor University

Medical Center includes transplant pulmonologists, surgeons,

coordinators, social workers, physical therapists, respiratory

therapists, anesthesiologists, nutritionists and nurses who

work together to provide the best possible quality outcomes

for patients. We provide a rapid, comprehensive evaluation to

determine the appropriateness and timing of transplantation.

Transplant outcomes at Baylor University Medical Center

are excellent and continue to improve with one-year survival

despite increased patient acuity. Waitlist times continue

to decrease as transplant volumes steadily increase.

LUNG

24

RESEARCH

25

Transplantation of the Liver, edited by Drs. Klintmalm at

Baylor Annette C. and Harold C. Simmons Transplant

Institute and Busuttil at UCLA, is the universally used

textbook in liver transplantation. First published in 1996,

the third edition was available in December 2014. Many of

the chapters in the textbook were authored by physicians on

the medical staff at Baylor, as well as other world-recognized

leaders in their fields.

Another textbook, Medical Care of the Liver Transplant Patient,

was published in December 2012 and authored/edited by

James Trotter, MD, medical director of liver transplantation at

Baylor Dallas, and Pierre-Alain Clavien, MD, PhD, professor

and chairman, Department of Transplantation Surgery at

the University of Zurich, Switzerland. This textbook for

hepatologists is the most current clinical guide on how

to best treat liver transplant recipients.

Liver Transplant Research Database System

In 1985, at the beginning of the liver transplant program,

Baylor created the Liver Transplant Research Database System

(LTRDS). Today it’s the longest existing, most detailed liver

transplant research database in the world. Collecting data

from patients before transplant and throughout their lives, this

research database has been the foundation for our worldwide

recognition as a major contributor in liver transplantation.

Due to significant donations made to Simmons Transplant

Institute, we are developing such research databases for our

heart, lung, kidney, pancreas and islet transplant divisions.

We plan to go live with these updated research databases

in 2015. With complete new heart and lung transplant

teams, we expect major research activity to develop in

these organ systems similar to that for liver transplant.

Transplant Biorepository

We also created the Biorepository in 1985. Blood samples

have been collected from organ donors and from transplant

recipients at regular intervals for the rest of their lives. We took

the Biorepository public in November 2009 and immediately

received worldwide attention. Many presentations and

scientific publications have resulted from our Biorepository.

Moreover, Baylor is a global leader in the field of antibody-

caused injury to liver transplants. We are now establishing

biorepositories for the other organ transplants.

It takes more than research databases and biorepositories to

generate research. The investigators are critical. These are the

individuals who are driven to find the answers to unanswered

questions from medical school, residency and fellowship.

They come to us with a research history, but first they have

to be identified, recruited and then mentored. Our worldwide

presence in the transplant community is the direct outcome

of Baylor’s dedication to nurturing the passions of researchers

and pioneering transplant medicine— a dedication we have

embraced since our beginning in 1985. Both Simmons

Transplant Institute and the Baylor Health Care System

Foundation are committed to continue raising community

support for this goal. The future of transplantation and the

lives of our patients depend on it.

In 2014, physicians on the medical staff at the Baylor Annette C. and Harold C. Simmons Transplant Institute and Institute scientists gave 53 scientific presentations around the world, and published 40 abstracts and 76 peer-reviewed publications.

SCIENTIFIC PRESENTATIONS WORLDWIDE53

RESEARCH

26

OUTREACHAUSTIN·AMARILLO· MCKINNEY· FR ISCO WAXAHACHIE·ODESSA·LUBBOCK LONGVIEW·MIDLOTHIAN & BEYOND

27

Teams of physicians, nurses and assistants travel to outreach

clinics throughout Texas, delivering world-renowned

transplantation medicine to an expanding network of

communities. The clinics are an outreach service of Health

Texas Provider Network.

Liver Health Clinics

Baylor’s Liver Health Clinics bring liver care to those

unable to travel to Baylor Dallas or Baylor Fort Worth to

see a liver specialist. Hepatologists travel to nine outreach

clinics throughout Texas to see patients with viral hepatitis,

cirrhosis, liver masses and other liver conditions, providing

people in outlying communities access to a wider range

of treatment options.

Outreach Centers for Advanced Heart Disease

Baylor’s innovative outreach program gives patients in areas

with limited health resources access to a full range of treatment

options for advanced heart disease. Outreach teams travel to six

locations in Texas to evaluate heart disease patients, including

evaluation for heart transplantation or LVADs. Often, LVAD

implantation is not available in smaller, outlying communities.

Baylor also has initiated LVAD Visitation Days, which allow

referring cardiologists to come to Baylor Dallas to learn about

LVADs, both as a bridge to transplant and as a destination

therapy. With more understanding of the LVADs, physicians

are better equipped to refer their patients to the program and,

if they choose, to assist with managing their patients when they

return home after implantation.

Kidney Transplant Outreach Clinic

Many people do not believe they are eligible for kidney

transplant when, in fact, they are. For others, routinely

traveling to the Dallas Fort Worth area isn’t feasible.

To serve such patients in West Texas and the Panhandle,

Baylor established weekly Kidney Transplant Outreach

Clinics in Lubbock and Amarillo to offer evaluations and

post-transplant care. When a patient receives a kidney

transplant, our goal is to get the patient home within two

to three weeks, where the patient can be closely followed by

the transplant team in the outreach clinic. Baylor maintains

close communication with the patient’s referring nephrologist,

keeping them continually apprised of their patient’s progress.

For people who live with liver, kidney or heart disease, but do not live near Baylor Annette C. and Harold C. Simmons Transplant Institute, we bring 30 years of transplant experience to them.

LIVER CLINICS

HEART CLINICS

KIDNEY CLINICSIN 2

014

52

9 T E X A S

Midlothian

Frisco

Grand Prairie

Waxahachie

McKinney

Odessa

Lubbock

Longview

Austin

Dallas-Fort Worth

Liver Kidney Heart

Abilene

Amarillo

2014 Transplant Outreach Clinics

OUTREACH

28

DONORCOMMUNITY

29

Baylor Honors DPS for Dramatic Rise in Organ Donors

It is rare that a government agency receives an award from the

private sector for doing a good job. But Baylor Health Care

System turned the tables, awarding the Texas Department of

Public Safety (DPS) the Barry and Ceil Newman Award for

its efforts to lift the state’s organ donation registry from the

bottom of the heap to the nation’s fastest-growing list. The

award was presented May 12, 2014.

Only about 2 percent of Texas adults were registered organ

donors in 2009, according to the nonprofit Donate Life Texas.

That rate has risen to about 25 percent, according to DPS.

The reason? The creation of an organ donor registry by

two state agencies—the DPS and the Department of

Motor Vehicles— and three organ tissue recovery agencies.

The registry makes it easy for residents to sign up at their local

DPS office when applying for or renewing a driver’s license

or identification card.

Living Donor Wall

In June 2013, Baylor University Medical Center became the

home of the Living Donor Wall, honoring living donors who

have made kidney or liver donations going back to 2011.

Consenting donors’ names are added to the wall yearly, in

recognition of their generosity and compassion and to raise

awareness of organ donation.

Donor Advocate Symposium

The third annual Donor Advocate Symposium, led by Giuliano

Testa, MD, was held in October 2014. Because living donor

transplantation is so vital to patients with severe kidney or liver

disease or end-stage organ failure, the symposium helps nurses,

clinicians, social workers and clergy communicate the living

donor option to patients, family, friends and potential living

donors. Topics covered include cost, psychosocial and ethical

issues, long-term donor health, paired donation, transplant

outcomes and the role of the media. The symposium’s goal

is to increase participation in the living donor process.

Göran Klintmalm, MD, PhD, FACS, presents the Barry and Ceil Newman Award to Salestus Winkley from the Department of Public Safety May 12, 2014. Dr. Klintmalm is chairman and chief of Baylor’s Annette C. and Harold C. Simmons Transplant Institute.

It takes a village to raise donor awareness. It takes living donors and recipients to promote more participation. It takes public and private entities collaborating to boost enrollment on registries. And it takes an institution committed to spotlighting the immeasurable value of the gift of life.

Christina Pippin, John Brinlee, Jr., Giuliano Testa, MD, FACS, and Michelle Brennan Hall at the second annual Donor Advocate Symposium.

COMMUNITY

30

2013 Liver and Kidney PublicationsKlintmalm G, O’Farrely C. Taking the rap: Multiple effects of blocking mammalian target of rapamycin. Journal of Hepatology 2013, Jan;57(1): 1-3.

McKenna GJ, Trotter JF, Klintmalm E, Ruiz R, Onaca N, Testa G, Saracino G, Levy MF, Goldstein RM, Klintmalm GB. Sirolimus and cardiovascular disease risk in liver transplantation. Transplantation; Vol.95: No 1: Jan. 15, 2013: 215-221.

Kim, PTW, Onaca N., Chinnakotla S., Davis GL, Jennings LW, McKenna GJ, Ruiz RM, Levy MF, Goldstein R, Klintmalm GB. Tumor biology and pre-transplant loco regional treatments determine outcomes in patients with T3 hepatocellular carcinoma undergoing liver transplantation. Clin Transp. Mar-Apr 2013;Vol.27;No.2;Pg:311-318.

O’Leary JG, McKenna GJ, Klintmalm GB, Davis GL. Effect of Telaprevir on the Pharmacokinetics of Sirolimus in Liver Transplant Recipients. Liver Transplantation 19:463-465, 2013; Letter to the Editor.

O’Leary JG, Gebel HM, Ruiz R, Bray RA, Marr JD, Zhou XJ, Shiller SM, Susskind BM, Kirk AD, and Klintmalm GB. Class II alloantibody and mortality in simultaneous liver-kidney transplantation. AJT 2013; Apr; 13 (4): 954-60.

Biggins SW, Trotter J, Gralla J, Burton JR, Bambha KM, Dodge J, Brocato M, Cheng L, McQueen M, Forman L, Chang M, Kam I, Everson G, Spritz RA, Klintmalm G, Rosen HR. Differential effects of donor and recipient IL28B and DDX58 SNP’s on severity of HCV after liver transplantation. Jour Hep. 2013; May:58(5): 969-76.

O’Leary JG, Klintmalm GB. Impact of donor-specific antibodies on results of liver transplantation. Liver Transplantation 2013; Jun;Vol. 8; No. 3, Pg. 279-284.

Kaneku H, O’Leary JG, Banuelos N, Jennings LW, Susskind BM, Klintmalm GB, and Terasaki PI. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. AJT, June 2013: Vol 13: Issue 6: 1541-1548.

Campsen J, Zimmerman M, Trotter J, Hong J, Freise C, Brown R, Cameron A, Ghobrial M, Kam I, Busuttil R, Saab S, Holt C, Emond J, Stiles J, Lukose T, Chang M, and Klintmalm G. Liver transplantation for hepatitis B liver disease and concomitant hepatocellular carcinoma in the United States with hepatitis B immunoglobulin and nucleoside/nucleotide analogues. Liver Transp 2013; Vol. 19; Pg. 1020-1029.

O’Leary JG, Kaneku H, Jennings LW, Banuelos N, Susskind BM, Terasaki PI, and Klintmalm GB. Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation. Liver Transplantation Vol. 19; No. 9; Sept. 2013 pg. 973-980.

O’Leary JG, McKenna G, Klintmalm GB, Davis GD. The effect of Telaprevir on the pharmacokinetics of Sirolimus in liver transplant recipients. Liver Transplantation 19:463-5, 2013.

Campsen J, Zimmerman M, Trotter J, Hong J, Freise C, Brown RS Jr., Cameron A, Ghobrial M, Kam I, Busuttil R, Saab, Holt C. Emond JC, Stiles JB, Lukose T, Chang MS, and Klintmalm G. Multicenter review of liver transplant for hepatitis B-related liver disease: disparities in gender and ethnicity. Clinical Transplantation, Vol. 27; No. 6; Nov-Dec. 2013; pg. 829-837.

O’Leary JG, Kaneku H, Demetris AJ, Marr JD, Shiller SM, Susskind BM, Tillery W, Terasaki PI, Klintmalm GB. Antibody mediated rejection as a contributor to previously unexplained early liver allograft loss. Liver Transplantation 2013; Nov 6; doi: 10.1002/lt.23788.

Auxiliary liver transplant is an ineffective treatment of primary hyperoxaluria. Trotter JF, Milliner D. Am J Transplant. 2014 Jan; 14(1):241. doi: 10.1111/ajt.12535. Epub 2013 Dec 12.

Risk of Hernia Incarceration following Transjugular Intrahepatic Portosystemic Shunt Placement. Smith MT, Rase B, Woods A, Trotter J, Gipson M, Kondo K, Ray C, Durham J. J Vasc Interv Radiol. 2014 Jan;25(1):58-62. doi: 10.1016 /j.jvir .2013. 09.003. Epub 2013 Oct 24.

Sporothrix schenckii Lymphadentitis in a Male with X-linked Chronic Granulomatous Disease. A Comparison of Outcomes Between OKT3 and Antithymocyte Globulin for Treatment of Steroid-Resistant Rejection in Hepatitis C Liver Transplant Recipients. Benjamin MM, Dasher KJ, Trotter JF. Transplantation. 2013 Oct 17.

Is disease recurrence still relevant to graft survival? Trotter JF. Liver Transpl. 2013 Nov;19 Suppl 2:S49-55. doi: 10.1002/lt.23750.

Multicenter review of liver transplant for hepatitis B-related liver disease: disparities in gender and ethnicity. Campsen J, Zimmerman M, Trotter J, Hong J, Freise C, Brown RS Jr, Cameron A, Ghobrial M, Kam I, Busuttil R, Saab S, Holt C, Emond JC, Stiles JB, Lukose T, Chang MS, Klintmalm G. Clin Transplant. 2013 Nov; 27 (6):829-37. doi: 10.1111/ctr.12224. Epub 2013 Sep 3.

Computerized assessment of competence-related abilities in living liver donors: the Adult-to-Adult Living Donor Liver Transplantation Cohort Study. Freeman J, Emond J, Gillespie BW, Appelbaum PS, Weinrieb R, Hill-Callahan P, Gordon EJ, Terrault N, Trotter J, Ashworth A, Dew MA, Pruett T; A2ALL Study Group. Clin Transplant. 2013 Jul-Aug;27(4):633-45. doi: 10.1111/ctr.12184. 2013 Jul 16.

Liver transplantation for hepatitis B liver disease and concomitant hepatocellular carcinoma in the United States with hepatitis B immunoglobulin and nucleoside/nucleotide analogues. Campsen J, Zimmerman M, Trotter J, Hong J, Freise C, Brown R, Cameron A, Ghobrial M, Kam I, Busuttil R, Saab S, Holt C, Emond J, Stiles J, Lukose T, Chang M, Klintmalm G. Liver Transpl. 2013 Sep;19(9):1020-9. doi: 10.1002/lt.23703.

Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial. Teperman L, Moonka D, Sebastian A, Sher L, Marotta P, Marsh C, Koneru B, Goss J, Preston D, Roberts JP; Spare-the-Nephron Trial Liver Transplantation Study Group. Liver Transpl. 2013 Jul;19(7):675-89. doi: 10.1002/lt.23658.

Underreporting of liver transplant waitlist removals due to death or clinical deterioration: results at four major centers. Goldberg D, French B, Trotter J, Shetty K, Schiano T, Reddy KR, Halpern SD. Transplantation. 2013 Jul 27;96(2):211-6. doi: 10.1097/TP.0b013e3182970619.

Early use of renal-sparing agents in liver transplantation: a closer look. Trotter JF, Grafals M, Alsina AE. Liver Transpl. 2013 Aug;19(8):826-42. doi: 10.1002/lt.23672.

Predicting end-stage renal disease after liver transplant. Israni AK, Xiong H, Liu J, Salkowski N, Trotter JF, Snyder JJ, Kasiske BL. Am J Transplant. 2013 Jul;13(7):1782-92. doi: 10.1111/ajt.12257. 2013 May 13.

Ascites with elevated protein content as the presenting sign of constrictive pericardial disease. George BA, Deprisco G, Trotter JF, Henry AC 3rd, Stoler RC. Proc (Bayl Univ Med Cent). 2013 Apr;26(2):168-70.

Kayser-Fleischer rings of acute Wilson’s disease. Mantas AM, Wells J, Trotter J. Proc (Bayl Univ Med Cent). 2013 Apr; 26(2):166-7.

Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation. Biggins SW, Trotter J, Gralla J, Burton JR Jr, Bambha KM, Dodge J, Brocato M, Cheng L, McQueen M, Forman L, Chang M, Kam I, Everson G, Spritz RA, Klintmalm G, Rosen HR. J Hepatol. 2013 May;58(5):969-76. doi: 10.1016/j.jhep.2012.12.027. 2013 Jan 15.

Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment. Rahimi RS, Landaverde C. Nutr Clin Pract. 2013 Feb;28(1):40-51. 2013 Jan 3. Review.

Wong F, O’Leary JG, Reddy KR, Patton H, Kamath PS, Fallon MB, Garcia-Tsao G, Subramanian RM, Malik R, Maliakkal B, Thacker LR, Bajaj JS. Validation of the New Consensus Definition of Acute Kidney Injury in Predicting Mortality in Infected Cirrhotic Patients. Gastroenterology 145: 1280, 2013.

Michael M, Campbell P, Gebel H, Randhawa P, Rodriguez R, Colvin R, Conway J, Hachem R, Halloran P, Keshavjee S, Nickerson P, Murphey C, O’Leary J, Reeve J, Tinckam K, Reed EF. Meeting Report: 2012 CST- AST JOINT SESSION: Precision Diagnostics in Transplantation: From Bench to Bedside. AJT 13:562-8; 2013.

PTW Kim, J-H Jang, EG Atenafu, S Fischer, PD Greig, ID McGilvray, AC Wei, C-A Moulton, S Gallinger, SP Cleary. Outcomes after liver resection and subsequent multimodality treatment of recurrence for multifocal hepatocellular carcinoma: An experience at North American Center. Br J Surg 2013;100:1516-1422.

PTW Kim, N Onaca, S Chinnakotla, GL Davis, LW Jennings, GJ McKenna, RM Ruiz, MF Levy, R Goldstein, and GB Klintmalm. Tumor biology and pretransplant locoregional treatments determine outcomes in patients with T3 hepatocellular carcinoma undergoing liver transplantation. Clin Transplant 2013;27(2):311-8.

PTW Kim, AC Wei, EG Atenafu, D Cavallucci, SP Cleary, CA Moulton, PD Greig, S Gallinger, S Serra, ID McGilvray. Partial versus circumferential portal vein resections in pancreaticoduodenectomy for pancreas cancer: Planning makes a difference. Br J Surg 2013;100(10):1349-56.

PUBLICATIONS

31

Wong F, O’Leary JG, Reddy KR, Patton H, Kamath PS, Fallon MB, Garcia-Tsao G, Subramanian RM, Malik R, Maliakkal B, Thacker LR, Bajaj JS. Validation of the New Consensus Definition of Acute Kidney Injury in Predicting Mortality in Infected Cirrhotic Patients. Gastroenterology 145: 1280, 2013.

Michael M, Campbell P, Gebel H, Randhawa P, Rodriguez R, Colvin R, Conway J, Hachem R, Halloran P, Keshavjee S, Nickerson P, Murphey C, O’Leary J, Reeve J, Tinckam K, Reed EF. Meeting Report: 2012 CST-AST JOINT SESSION: Precision Diagnostics in Transplantation: From Bench to Bedside. AJT 13:562-8; 2013.

Rahimi RS, Guntipalli P, Rockey DC. Worldwide Practices for Pharmacologic Therapy in Esophageal Variceal Hemorrhage. Scand J Gastroenterol. 2013 Nov 30.

Singal AG, Rahimi RS, Clark C, Ma Y, Cuthbert JA, Rockey DC, Amarasingham R.An Automated Model Using Electronic Medical Record Data Identifies Patients with Cirrhosis at High Risk for Readmission. Clin Gastroenterol Hepatol. 2013 Oct; 11(10):1335-1341.

Rahimi RS, Elliott AC, Rockey DC. Altered Mental Status in Cirrhosis: Etiologies and Outcomes. J Investig Med. 2013 Apr; 61(4):695-700.

Rahimi RS, Landaverde C. Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: Clinical Implications and Treatment. Nutr Clin Pract. 2013 Feb: 28 (1):40-51.

A Comparison of Outcomes Between OKT3 and Antithymocyte Globulin for Treatment of Steroid-Resistant Rejection in Hepatitis C Liver Transplant Recipients. Benjamin MM, Dasher KJ, Trotter JF. Transplantation. 2013 Oct 17.

Early use of renal-sparing agents in liver transplantation: a closer look. Trotter JF, Grafals M, Alsina AE. Liver Transpl. 2013 Aug;19(8):826-42. doi: 0.1002/lt.23672.

Predicting end-stage renal disease after liver transplant. Israni AK, Xiong H, Liu J, Salkowski N, Trotter JF, Snyder JJ, Kasiske BL. Am J Transplant. 2013 Jul;13(7):1782-92. doi: 10.1111/ajt.12257. 2013 May 13.

Ascites with elevated protein content as the presenting sign of constrictive pericardial disease. George BA, Deprisco G, Trotter JF, Henry AC 3rd, Stoler RC. Proc (Bayl Univ Med Cent). 2013 Apr;26(2):168-70.

Computerized assessment of competence-related abilities in living liver donors: the Adult-to-Adult Living Donor Liver Transplantation Cohort Study. Freeman J, Emond J, Gillespie BW, Appelbaum PS, Weinrieb R, Hill-Callahan P, Gordon EJ, Terrault N, Trotter J, Ashworth A, Dew MA, Pruett T; A2ALL Study Group. Clin Transplant. 2013 Jul-Aug;27(4):633-45. doi: 10.1111/ctr.12184. 2013 Jul 16.

Underreporting of liver transplant waitlist removals due to death or clinical deterioration: results at four major centers. Goldberg D, French B, Trotter J, Shetty K, Schiano T, Reddy KR, Halpern SD. Transplantation. 2013 Jul 27;96(2):211-6. doi: 10.1097/TP.0b013e3182970619.

Saracino G, Jennings LW, Hasse JM. Basic statistical concepts in nutrition research. Nutr Clin Pract. 2013 Apr:28(2):182-93.

Lagow EE, Leeper BB, Jennings LW, Ramsay MA. Incidence and severity of respiratory insufficiency detected by transcutaneous carbon dioxide monitoring after cardiac surgery and intensive care unit discharge. Proc (Baylor University).

West Nile Virus Infection in Kidney and Pancreas Transplant Recipients in the Dallas-Fort Worth Metroplex During the 2012 Texas Epidemic. Yango AF, Fischbach BV, Levy M, Chandrakantan A, Tan V, Spak C, Melton L, Rice K, Barri Y, Rajagopal A, Klintmalm G. Saracino G, Jennings LW, Hasse JM. Basic statistical concepts in nutrition research. Nutr Clin Pract. 2013;28(2):182-193.

Hasse JM. Developing the “write” skills for publishing. Nutr Clin Pract. 2013;28(2):153-157.

Hasse JM. Nutrition and liver disease: complex connections. Nutr Clin Pract.2013;28(1):12-14. (editorial)

2014 Liver and Kidney PublicationsKlintmalm GB, Feng S, Lake JR, Vargas HE, Wekerle T, Agnes S, Brown KA, Nashan B, Rostaing L, Meadows-Shropshire S, Agarwal M, Harler MB, Garcia-Valdecasas JC. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. AJT; 2014 Aug; 14(8):1817-27.

Klintmalm GB, Saab S, Hong JC, Nashan B. The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy. Clinical Transplantation; 2014 Jun; 28(6):635-48.

Klintmalm GB. Carl Gustav Groth MD, PhD. Clinical Transplantation 2014 Apr; 28(4):383.

Klintmalm GB, Nashan B. The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence. Journal of Transplantation; 2014:845438.

Trotter JF, Lizardo-Sanchez L. Everolimus in liver transplantation. Current Opinion Organ Transplant; 2014 Dec; 19(6):578-82.

Trotter JF. Challenges in living donor liver transplantation. Clinical Liver Dis.; 2014 Aug; 18(3):651-60; 2014.05.007.

Trotter JF, Goldberg DS, Krok K, Batra S, Kawut SM, Fallon MB. Impact of the hepatopulmonary syndrome MELD exception policy on outcomes of patients after liver transplantation: an analysis of the UNOS database. Gastroenterology; 2014 May; 146 (5):1256-65.e1.

Trotter JF, Valley MA, Thomas D, Ginde AA, Lowenstein SR, Honigman B. The relationship between hepatopulmonary syndrome and altitude. Canadian Journal of Gastroenterology & Hepatology; 2014 Mar; 28(3):140-2.

Trotter JF, Benjamin MM, Dasher KJ. A comparison of outcomes between OKT3 and antithymocyte globulin for treatment of steroid-resistant rejection in hepatitis C liver transplant recipients. Transplantation; 2014 Feb 27; 97(4):470-3.

Trotter JF, Milliner D. Auxiliary liver transplant is an ineffective treatment of primary hyperoxaluria. American Journal of Transplantation; 2014 Jan; 14(1):241.

Rahimi RS, Singal AG, Cuthbert JA, Rockey DC. Lactulose vs. Polyethylene Glycol 3350-Electrolyte Solution for Treatment of Overt Hepatic Encephalopathy: The HELP Randomized Clinical Trial. JAMA Internal Medicine; 2014 Nov 1; 174(11):1727-33.

Rahimi RS, Rockey DC. Hepatic encephalopathy: how to test and treat. Curr Opinion Gastroenterology; 2014 May; 30(3):265-71.

Rahimi RS, Guntipalli P, Rockey DC. Worldwide practices for pharmacologic therapy in esophageal variceal hemorrhage. Scand J Gastroenterology; 2014 Feb; 49(2):131-7.

Perrillo RP, Di Bisceglie AM, Lok AS, Martin P, Terrault N, Hoofnagle JH. Recent FDA warnings on hepatitis B reactivation with immune-suppressing and anti-cancer drugs: Just the tip of the iceberg? Hepatology; 2014 Nov 21.

Perrillo RP, Hwang JP, Barbo AG. Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver Diseases. Journal of Viral Hepatology; 2014 Sep 15.

Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Reactivation during Immunosuppressive Drug Therapy. Gastroenterology; 2014 Oct 31.

Asrani SK, Shah VH. Alcohol Related Liver Damage. Expert Round Table; July 2014: 65:7 Gastroenterology and Endoscopy News.

Asrani SK, Kamath PS. Editorial: neutrophil dysfunction in patients with cirrhosis. Aliment Pharmacol Ther; 2014 Oct;40(8):986.

Asrani SK. Liver transplantation for NASH. Clin Gastroenterol Hepatol.; 2014 Mar;12(3):403-4.

Asrani SK, Talwalkar JA, Kamath PS, Shah VH, Saracino G, Jennings L, Gross JB. Role of magnetic resonance elastography in compensated and decompensated disease. J Hepatol.; 2014 May;60(5):934-9.

Asrani SK, Wiesner RH, Trotter JF, Klintmalm G, Katz E, Maller E, Roberts J. De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: The 2000-2003 phase II prospective randomized trial. AJT; Feb; 14(2):356-66.

Asrani SK, O’Leary LG. Acute-on-chronic liver failure. Clinical Liver Disease Aug; 18(3):561-74.

Asrani SK, Davis GL. Impact of birth cohort screening for hepatitis C. Curr Gastroenterol; 2014 Apr;16 (4):381.

Asrani SK, Kumar S, Kamath PS. Epidemiology, Diagnosis and Early Patient Management of Esophagogastric Hemorrhage. Gastroenterol Clinical North Am.; 2014 Dec; 43(4):765-782.

O’Leary JG. Debate—a bridge too far: Nonalcoholic fatty liver disease will not exhaust the donor pool. Liver Transpl.; 2014 Nov;20 Suppl 2:s38-41.

O’Leary JG, Schiller SM, Bellamy C, Nalesnik MA, Kaneku H, Jennings LW, Isse K, Terasaki PI, Klintmalm GB, Demetris AJ. Acute liver allograft antibody-mediated rejection: an inter-institutional study of significant histopathological features. Liver Transpl.; 2014 Oct;20(10):1244-55.

31

PUBLICATIONS

32

O’Leary JG, Campos-Varela I, Lai JC, Verna EC, Todd Stravitz R, Forman LM, Trotter JF, Brown RS, Terrault NA. Hepatitis C Genotype Influences Post-Liver Transplant Outcomes. Transplantation; 2014 Sep 10.

Burton JR, O’Leary JG, Verna EC, Saxena V, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS Jr, Terrault NA. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol.; 2014 Sep;61(3):508-14.

O’Leary JG, Reddy KR, Wong F, Kamath PS, Patton HM, Biggins SW, Fallon MB, Garcia-Tsao G, Subramanian RM, Malik R, Thacker LR, Bajaj JS. Long-term Use of Antibiotics and Proton Pump Inhibitors Predict Development of Infections in Patients with Cirrhosis. Clin Gastroenterol Hepatol.; 2014 Aug 12. pii: S1542-3565(14)01146-X.

Bajaj JS, O’Leary JG, Reddy KR, Wong F, Biggins SW, Patton H, Fallon MB, Garcia-Tsao G, Maliakkal B, Malik R, Subramanian RM, Thacker LR, Kamath PS. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology; 2014 Jul;60(1):250-6.

O’Leary JG, Kaneku H, Jennings L, Susskind BM, Terasaki PI, Klintmalm GB. Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients. Liver Transpl.; 2014 Jun;20(6):655-63.

O’Leary JG, Demetris AJ, Friedman LS, Gebel HM, Halloran PF, Kirk AD, Knechtle SJ, McDiarmid SV, Shaked A, Terasaki PI, Tinckam KJ, Tomlanovich SJ, Wood KJ, Woodle ES, Zachary AA, Klintmalm GB. The role of donor-specific HLA alloantibodies in liver transplantation. AJT; 2014 Apr;14(4):779-87.

O’Leary JG, Kaneku H, Demetris AJ, Marr JD, Shiller SM, Susskind BM, Tillery GW, Terasaki PI, Klintmalm GB. Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss. Liver Transpl.; 2014 Feb;20(2):218-27.

O’Leary JG, Wong F, Reddy KR, Kamath PS, Garcia-Tsao G, Maliakkal B, Subramanian RM, Thacker LR, Bajaj JS; On behalf of North American Consortium in the Study of End-Stage Liver Disease. A cut-off serum creatinine value of 1.5mg/dL for AKI — To be or not to be. J Hepatol.; 2014 Dec 5. pii: S0168-8278(14)00888-5.

Serrano PE, Cleary SP, Dhani N, Kim PT, Greig PD, Leung K, Moulton CA, Gallinger S, Wei AC. Improved Long-Term Outcomes After Resection of Pancreatic Adenocarcinoma: A Comparison Between Two Time Periods. Ann Surg Oncol.; 2014 Oct 28.

Temple SJ, Kim PT, Serrano PE, Kagedan D, Cleary SP, Moulton CA, McGilvray ID, Gallinger S, Greig PD, Wei AC. Combined pancreaticoduodenectomy and colon resection for locally advanced peri-ampullary tumours: analysis of peri-operative morbidity and mortality. HPB (Oxford); 2014 Sep;16(9):797-800.

Lee JJ, Kim PT, Fischer S, Fung S, Gallinger S, McGilvray I, Moulton CA, Wei AC, Greig PD, Cleary SP. Impact of viral hepatitis on outcomes after liver resection for hepatocellular carcinoma: results from a North American center. Ann Surg Oncol.; 2014 Aug;21(8):2708-16.

Kim PT, Saracino G, Jennings L, Ramsay M, McKenna GJ, Testa G, Anthony TL, Onaca N, Ruiz RM, Goldstein RM, Levy MF, Klintmalm GB. Ratio of hepatic arterial flow to recipient body weight predicts biliary complications after deceased donor liver transplantation. HPB (Oxford); 2014 Jul 18.

Zarghouni M, Cura M, Kim PT, Testa G, Klintmalm GB. Segmental biliary duct N-butyl cyanoacrylate ablation in a transplant liver for a biliary leak after hepaticojejunostomy. Liver Transpl.; 2014 Jun;20(6):739-41.

Kim PT, Temple S, Atenafu EG, Cleary SP, Moulton CA, McGilvray ID, Gallinger S, Greig PD, Wei AC. Aberrant right hepatic artery in pancreaticoduodenectomy for adenocarcinoma: impact on resectability and postoperative outcomes. HPB (Oxford); 2014 Mar;16(3):204-11.

Testa G, deSante J, Caplan A, Hippen B, Lantos JD. Was Sarah Murnaghan treated justly? Pediatrics; 2014 Jul;134(1):155-62.

Testa G. Ethical issues regarding related and nonrelated living organ donors. World J Surg.; 2014 Jul;38(7):1658-63.

Laux AT, Testa G, Goldstein RM, Cavaness KM. The management of a complex bile duct injury after laparoscopic cholecystectomy. Am Surg.; 2014 Jun;80(6):E175-8.

Kheradmand T, Anthony TL, Harland RC, Testa G, Hart J, Renz J, Te HS, Marino SR. Antibody-mediated rejection in ABO compatible husband to wife living donor liver transplant and review of the literature. Hum Immunol.; 2014 Jun;75(6):578-83.

Hafzalah M, Azzam R, Testa G, Hoehn KS. Improving the potential for organ donation in an inner city Muslim American community: the impact of a religious educational intervention. Clin Transplant.; 2014 Feb;28(2):192-7.

2013 Islet Cell Publications“Autoimmune chronic pancreatitis with IgG4-related pancreatic pseudocyst in a patient undergoing total pancreatectomy followed by autologous islet transplantation: a case report.” B.L. Bartlett, D. Chujo, T. Itoh, S. Iwahashi, M.F. Levy, S. Matsumoto, B. Naziruddin, N. Onaca, M. Shimoda, M. Takita, Y. Tamura. Pancreas. 42(1):175-177. 2013.

“Beta cell function after islet transplantation.” In “Type 1 Diabetes.” M.F. Levy, B. Naziruddin, S. Nigar, M. Takita. Editors: A.P. Escher, A. Li. InTech. Rijeka, Croatia. 167-194. 2013. “CD11b(+) cells in donor-specific transfusion prolonged allogenic skin graft survival through indoleamine 2,3-dioxygenase.” T. Ikemoto, M.F. Levy, B. Naziruddin, M. Shimada, M. Takita. Cell Immunol. 283(1-2): 81-90. 2013.

“Changes in metabolic profiles after the Great East Japan Earthquake: a retrospective observational study.” T. Hamaki,

K. Hara, M. Kami, K. Kobayashi, T. Matsumura, G. Oiso, T. Okawada, H. Tachiya, M. Takita, T. Tanimoto, M. Tsubokura. BMC Public Health. 13: 267. 2013.

“Withaferin A inhibits pro-inflammatory cytokine induced damage to islets in culture and following transplantation.” T. Itoh, M.A. Kanak, M.F. Levy, M.C. Lawrence, S. Matsumoto, B. Naziruddin, H. Peng, J.A. SoRelle, K. Sugimoto. Diabetologia. 56(4): 814-824. 2013.

2014 Islet Cell Publications“Alleviation of instant blood-mediated inflammatory reaction in autologous conditions through treatment of human islets with NF-κB inhibitors.” T. Itoh, M.A. Kanak, F. Kunnathodi, M.C. Lawrence, M.F. Levy, S. Murali, B. Naziruddin, R. Shahbazov, J.A. SoRelle, M. Takita. Transplantation. 98(5): 578-584. 2014.

“A new method for generating insulin-secreting cells from human pancreatic epithelial cells after islet isolation transformed by Neuro D1.” S. Chen, D. Chujo, P. Grayburn, T. Itoh, S. Iwahashi, M.F. Levy, S. Matsumoto, B. Naziruddin, H. Noguchi, M. Shimoda, K. Sugimoto, M. Takita. Human Gene Therapy Methods. 25(3): 206-219. 2014.

“Elevation of high-mobility group box 1 after clinical autologous islet transplantation and its inverse correlation with outcomes.” P.T. Coates, D. Chujo, W. Chung, A. Dennison, T. Itoh, S. Iwahashi, M.A. Kanak, M.F. Levy, S. Matsumoto, B. Naziruddin, N. Onaca, A.M. Rahman, M. Shimoda, M. Takita, Y. Tamura. Cell Transplant. 23(2): 153-165. 2014.

“Evidence for instant blood-mediated inflammatory reaction in clinical autologous islet transplantation.” T. Itoh, S. Iwahashi, M.A. Kanak, M.F. Levy, B. Naziruddin, M.

Takita. American Journal of Transplantation. 14(2): 428- 437. 2014.

“Improving allogeneic islet transplantation by suppressing Th17 and enhancing Treg with histone deacetylase inhibitors.” D. Chujo, T. Itoh, M.F. Levy, S. Matsumoto, B. Naziruddin, M. Shimada, M. Shimoda, J.A. Sorelle, K. Sugimoto, M. Takita. Transplant International. 27(4): 408-415. 2014.

“Inflammatory Response in Islet Transplantation.” M.A. Kanak, F. Kunnathodi, M.C. Lawrence, M.F. Levy, M. Takita. International Journal of Endocrinology. 2014: 451035. 2014.

“Islet Product Characteristics and Factors Related to Successful Human Islet Transplantation from the Collaborative Islet Transplant Registry (CITR) 1999-2010.”

R. Alejandro, A.N. Balamurugan, F.B. Barton, T. Berney, B.J. Hering, T.W.H. Kay, J. Kerr-Conti, T. Kin, C. Liu, A. Lockridge, G. Loganathan, P. Maffi, J. Markmann, S. Messinger, S. Matsumoto, B. Naziruddin, P.J. O’Connell, K. Papas, A. Posselt, M.R. Rickels, C. Ricordi, A. Secchi, M. Takita, M. Tiwari, M. Trieger, S. Wease, P. Witkowski, X. Zhang. American Journal of Transplantation. 14(11): 2595-2606. 2014.

“Pancreatic ductal perfusion at organ procurement enhances islet yield in human islet isolation.” T. Itoh, M.A. Kanak, F. Kunnathodi, M.C. Lawrence, M.F. Levy, B. Naziruddin, R. Shahbazov, M. Shimoda, M. Takita. Pancreas. 43(8): 1249-1255. 2014.

“Total pancreatectomy with islet autotransplantation: summary of a national institute of diabetes and digestive and kidney diseases workshop.” D.K. Andersen, G. Arreaza- Rubin, M.D. Bellin, T.B. Dunn, A. Gelrud, A. Humar, K.A. Morgan, B. Naziruddin, C. Rastellini, M.R. Rickels, S.J. Schwarzenberg. Pancreas. 43(8): 1163-1171. 2014.

PUBLICATIONS

33

2013 Heart and Lung Publications“Aortic valve and ascending aorta guidelines for management and quality measures: executive summary.” D.A. Adams, C.W. Akins, J. Bavaria, E.H. Blackstone, R.O. Bonow, T.E. David, R. D’Agostino, T. Dewey, T. Gleason, K.B. Harrington, S. Kapadia, S. Kodali, N. Kouchoukos, M. Leon, B. Lima, B. Lytle, M.J. Mack, D.C. Miller, P.T. O’Gara, B. Reece, G.R. Reiss, E.E. Roselli, H. Schaff, D. Shahian, C.R. Smith, L.G. Svensson, V. Thourani, M. Tuzcu, J. Webb, M.R. Williams. The Annals of Thoracic Surgery. 95(4): 1491-505. 2013.

“Bioprosthetic aortic valve changes late after insertion of a left ventricular assist device.” G.V. Gonzalez-Stawinski, K. Khvilivitzky. Baylor University Medical Center Proceedings. 26(1): 45-6. January 2013.

“Case series using the ROTAFLOW system as a temporary right ventricular assist device after HeartMate II implantation.” T. Chamogeorgakis, G.V. Gonzalez-Stawinski, M. Hanna, A. Khani-Hanjani, G. Loor, M. Mountis, A. Shafii, E. Soltesz. ASAIO Journal. 59(4): 456-60. July-August 2013.

“Chylopericardium Following Orthotopic Lung Transplantation.” J.E. Capehart, B.W. Hardaway, M.A. Ramsay, R.L. Rosenblatt, M.A. Wait. Baylor University Medical Center Proceedings. 26(3): 280-2. July 2013.

“Combined heart and liver transplantation: the Cleveland Clinic experience.” T. Chamogeorgakis, J. Fung, G.V. Gonzalez-Stawinski, M. Hanna, C.M. Miller, D. Nagpal, A.E. Shafii. The Annals of Thoracic Surgery. 95(1): 179-82. January 2013.

“Dramatically different phenotypic expressions of hypertrophic cardiomyopathy in male cousins undergoing cardiac transplantation with identical disease-causing gene mutation.” E. Capehart, P.A. Grayburn, S.A. Hall, J.M. Ko, J.J. Kuiper, W.C. Roberts, C.C. Roberts, A. Tandon. American Journal of Cardiology. 111(12): 1818-22. June 2013.

“Effect of postoperative course on midterm outcome after esophageal resection for cancer.” F. Bhora, T. Chamogeorgakis, C. Connery, A. Nabong, I. Toumpoulis. Baylor University Medical Center Proceedings. 26(3): 239-42. July 2013.

“HLA and MICA allosensitization patterns among patients supported by ventricular assist devices.” M. Askar, S. Bakdash, W. Baldwin, J. Daghstani, G.V. Gonzalez-Stawinski, E. Hsich, L. Klingman, N. Moazami, A.S. Nowacki, P. Reville, N. Smedira, R.C. Starling, D.O. Taylor, A. Zhang. The Journal of Heart and Lung Transplantation. 32(12): 1241-8. December 2013.

“Impact of nutritional state on lung transplant outcomes.” E.H. Blackstone, T. Chamogeorgakis, D.P. Mason, S.C. Murthy, G.B. Pettersson, D.P. Raymond, L. Thuita. The Journal of Heart and Lung Transplantation. 32(7): 693-700. July 2013.

“Modifications, classification, and outcomes of elephant-trunk procedures.” L.H. Batizy, E.H. Blackstone, A.M. Gillinov, B.W. Lytle, A.E. Rafael, E.E. Roselli, G.D. Rushing, J.F. Sabik, III, L.G. Svensson, E.S. Valenzuela. The Annals of Thoracic Surgery. 96(2): 548-58. August 2013.

“The myth of the Bernheim syndrome.” T. Chamogeorgakis, M.S. Chung, S.A. Hall, J.M. Ko, W.C. Roberts. Baylor University Medical Center Proceedings. 26(4): 401-4. October 2013.

“Outcomes of axillary artery side graft cannulation for extracorporeal membrane oxygenation.” T. Chamogeorgakis, G.V. Gonzalez-Stawinski, B. Lima, D. Mason, D. Nagpal, J.L. Navia, J.A. Pokersnik, A.E. Shafii. The Journal of Thoracic and Cardiovascular Surgery. 145(4): 1088-92. April 2013.

“Pathologic correlates of heparin-free donation after cardiac death in lung transplantation.” C.R. Brown, C.F. Farver, D.P. Mason, S.C. Murthy, G.B. Pettersson, A.E. Shafii. The Journal of Thoracic and Cardiovascular Surgery. 145(5): e49-50. May 2013.

“Timing of heparin and thrombus formation in donor lungs after cardiac death.” C.R. Brown, C.F. Farver, H.B. Keshava, D.P. Mason, S.C. Murthy, G.B. Pettersson, A.E. Shafii, N. Vakil, J.J. Yun. The Journal of Thoracic and Cardiovascular Surgery. 61(3): 246-50. April 2013.

“Which is better: a miniaturized percutaneous ventricular assist device or extracorporeal membrane oxygenation for patients with cardiogenic shock?” T. Chamogeorgakis, G.V. Gonzalez-Stawinski, D. Nagpal, J.A. Pokersnik, A. Rafael, A.E. Shafii. ASAIO Journal. 59(6): 607-11. November-December 2013.

2014 Heart and Lung Publications“Anomalous cord from the raphe of a congenitally bicuspid aortic valve to the aortic wall producing either acute or chronic aortic regurgitation.” G.V. Gonzalez-Stawinski, J.M. Ko, G.D. Trachiotis, B.J. Roberts, C.S. Roberts, W.C. Roberts, T.J. Vowels. Journal of the American College of Cardiology. 63(2): 153-7. Jan. 21, 2014.

“Bilateral Diaphragmatic Paralysis Associated with the Use of the Tumor Necrosis Factor-Alpha Inhibitor Adalimumab.” M. Benjamin, M.D.; A.W. Martin, M.D.; R. L. Rosenblatt, M.D. Baylor University Medical Center Proceedings. 27(2): 113-115. April 2014.

“Cardiac Restriction Secondary to Massive Calcific Deposits in the Left Ventricular Cavity.” P. A. Grayburn, M.D.; J.M. Guileyardo, M.D.; J.M. Ko, B.A.; J.J. Kuiper, M.D.; W.C. Roberts, M.D.; R.L. Rosenblatt, M.D. The American Journal of Cardiology. 15. 113(8): 1442-1448. April 2014.

“Expanding the Donor Pool: Donation after Cardiac Death.” H. Elgharably, D.P. Mason, A.E. Shafii. In-press, Thoracic Surgery Clinics.

“Fat in the ventricular septum.” T. Chamogeorgakis, E.E. Donaldson, J.M. Ko, J.J. Kuiper, W.C. Roberts. Baylor University Medical Center Proceedings. 27(3): 231-2. July 2014.

“Increased need for right ventricular support in patients with chemotherapy-induced cardiomyopathy undergoing mechanical circulatory support: outcomes from the INTERMACS Registry (Interagency Registry for Mechanically Assisted Circulatory Support).” M. Dupont, G.V. Gonzalez-Stawinski, S.L. Myers, D. Naftel, G.H. Oliveira, R.C. Starling, W.H. Tang, D.O. Taylor, J.B. Young, Y. Yuan. Journal of the American College of Cardiology. 63(3): 240-8. Jan. 28, 2014.

“Intracardiac abscess with cutaneous fistula secondary to ventricular septal defect repair simulating sternal wound infection.” S. Keshavamurthy, C.C. Miranda, T. Okamoto, G.B. Pettersson, A.E. Rafael, E. Sepulveda. Texas Heart Institute Journal. 41(3): 324-6. June 1, 2014.

“Microsporidiosis Acquired Through Solid Organ Transplantation: A Public Health Investigation.” M. de Almeida, Ph.D; S. Antony, M.D.; T. Benedict, B.S.; D.M. Blau, D.V.M., Ph.D; I. Castillo, R.N., B.S.N.; H. Diaz-Luna, M.D.; G.C. Friedman, M.D.; C.S. Goldsmith, M.G.S.; S.N. Hocevar, M.D.; M.J. Kuehnert, M.D.; S. Luna, R.N.; C.D. Paddock, M.D.; T. Peterson, R.N., M.S.N./M.P.H., C.P.T.C.; R. Rosenblatt, M.D.; A. da Silva, Ph.D; C.W. Spak, M.D.; R.R. Sriram, B.S.; R.A. Stoddard, D.V.M., Ph.D; R.V. Tiller, M.P.H.; G.S. Visvesvara, Ph.D; S.R. Zaki, M.D., Ph.D; for the Microsporidia Transplant Transmission Investigation Team. Annals of Internal Medicine. 160(4): 213-220. Feb. 18 2014.

“Morphologic features of cardiac sarcoidosis in native hearts of patients having cardiac transplantation.” J.E. Capehart, M.S. Chung, S.A. Hall, J.M. Ko, W.C. Roberts. American Journal of Cardiology. 113(4): 706-712. Feb. 15, 2014.

“Morphologic features of the recipient heart in patients having cardiac transplantation and analysis of the congruence or incongruence between the clinical and morphologic diagnosis.” Roberts WC, Roberts CC, Ko JM, Filardo G, Capehart JE, and Hall SA. Medicine. July 2014; 93(5):211-235.

“Secondary Arrhythmogenic Right Ventricular Cardiomyopathy Decades After Operative Repair of Tetralogy of Fallot.” E.E. Donaldson, G.V. Gonzalez-Stawinski, S.A. Hall, J.M. Ko, W.C. Roberts. American Journal of Cardiology. pii: S0002-9149(14)01273-9. June 18, 2014.

“Spectroscopic limb monitoring in peripheral extracorporeal membrane oxygenation.” S. Keshavamurthy, A.E. Shafii, E. Soltesz. Asian Cardiovascular and Thoracic Annals. June 6, 2014.

“Surgical repair of postoperative lymphoceles in cardiac transplant patients following inguinal lymphangiography with methylene blue dye injection.” T.J. Chamogeorgakis, P.A. Compton, M.A. Cura, J.D. Sacks. Journal of Vascular and Interventional Radiology. 25(4): 656-8. April 2014.

“Too High for Transplantation? Single-Center Analysis of the Lung Allocation Score.” E. Blackstone, C. Brown, M. Budev, D. Mason, S. Murthy, G. Pettersson, A.E. Shafii, L. Thuita. In-press, The Annals of Thoracic Surgery.

“Treatment of Left Ventricular Assist Device–Associated Arteriovenous Malformations with Thalidomide.” R. Ha, P.P. Kale, R. Ray. ASAIO Journal. 60(4): 482-483. July/August 2014.

“Utility of cardiac computed tomography for inflow cannula patency assessment and prediction of clinical outcome in patients with the HeartMateII left ventricular assist device.” J. Sacks, MD, G. Gonzalez-Stawinski, MD, S. Hall, MD, W. Dockery, MD, M. Cura, MD, B. Lima, MD, and T. Chamogeorgakis, MD.. Jnl of Cardiovascular Computed Tomography. (submitted 2014).

33

PUBLICATIONS

34

Abdominal Transplant SurgeonsGöran B. Klintmalm, MD, PhD, FACS Chairman and Chief, Baylor Simmons Transplant Institute; Vice Chair, Department of Surgery; Division Chief, Transplant SurgeryRobert M. Goldstein, MD, FACS Assistant Director, Transplant Surgery; Surgical Director, Hepatobiliary Surgery; Director, LPC

Marlon F. Levy, MD, FACS Surgical Director, Baylor All Saints Transplant Program;

Medical Director, Pancreas, Islet Cell ProgramGiuliano Testa, MD, FACS, MBA Surgical Director, Living Donor Liver TransplantationTiffany Anthony, MD Director, Laparoscopic Donor NephrectomyPeter Tae Wan Kim MD, MSc, FRCS(C) Assistant Director, Living Donor Liver TransplantationGregory J. McKenna, MD, FRCS(C), FACS Director, Liver Transplant Surgical ResearchNicholas Onaca, MD Surgical Director, Kidney TransplantationRichard M. Ruiz, MD, FACS Director, Pancreas Transplantation; Director, Transplant Fellowship Program

Heart Transplant SurgeonsGonzalo Gonzalez-Stawinski, MD Chief of Heart Transplantation and Mechanical Circulatory Support and Chief of Cardiac Services for Baylor Dallas

Themistokles Chamogeorgakis, MD Associate Director of Heart Transplantation & Mechanical Circulatory Support;

Medical Director of Quality for CV Surgical ServicesBrian Lima, MD Director of Clinical Research, Heart Transplantation and Mechanical Circulatory Support

Juan MacHannaford, MD Vice Chairman of CV Surgical ServicesAldo Rafael, MD

Lung Transplant SurgeonsDavid P. Mason, MD Chief of Thoracic Surgery and Lung Transplantation, Baylor Scott and White

Alexis Shafii, MD Associate Director of Lung Transplantation; Director of ECMOAldo Rafael, MDThemistokles Chamogeorgakis, MD

CardiologistsShelley A. Hall, MD, FACC Chief of Transplant Cardiology and Mechanical Circulatory Support/Heart Failure

Johannes J. Kuiper, MD Director, Outreach and Shared CareJose Mendez, MDAmarinda Bindra, MDParag Kale, MDAdnan Khalid, MD

HepatologistsJames Trotter, MD Program Director for General and Transplant Hepatology BHCS

Natalie G. B. Murray, MD Medical Director Liver Transplant, BASMCJacqueline O’Leary, MD, MPH Medical Director of Hepatology Research and Liver UnitMohammad Ashfaq, MDSumeet Asrani, MD, MSCManjushree Gautam, MD, MASStevan A. Gonzalez, MD, MSLinsheng Guo, MDCarmen Landaverde, MDMaria Lepe, MD Director, Hepatology Fellowship ProgramApurva A. Modi, MDRobert Perrillo, MDRobert S. Rahimi, MD, MSCRJennifer T. Wells, MD

NephrologistsBernard V. Fischbach, MD Medical Director of Renal and Pancreas TransplantationSteven Hays, MD Medical Director, Living Donor Kidney ProgramYousri Barri, MDArun Chandrakantan, MDLarry Melton, MDImran Memon, MD Patrick Nef, MDArthi Rajagopal, MDKim Rice, MDAngelito Yango, MD

PulmonologistsRandall L. Rosenblatt, MD, MACP, FACCP Chief of Pulmonary and Critical Care Medicine; Medical Director, Lung TransplantationHoward J Huang, MD Assistant Medical Director, Lung TransplantationKenneth Ausloos, MD Medical Director, Interstitial Lung Disease and Pulmonary Hypertension

Mark Millard, MD Medical Director, Martha Foster Lung Center

MEDICAL STAFF

35

Hepatology Team Back row L to R: James Trotter, MD; Linsheng

Guo, MD; Apurva A. Modi, MD; Jennifer Wells, MD;

Mohammed Ashfaq, MD; Carmen Landaverde, MD;

Stevan A. Gonzalez, MD, MS; Robert Rahimi, MD.

Front row L to R: Manjushree Gautam, MD, MAS;

Jacqueline O’Leary, MD, MPH; Sumeet Asrani, MD;

Natalie G.B. Murray, MD; Rita Lepe-Suastegui, MD

Not pictured: Robert Perrillo, MD

Heart Team Shelley Hall, MD; Johannes Kuiper, MD;

Juan MacHannaford, MD; Aldo Rafael, MD;

Gonzalo Gonzalez-Stawinski, MD; Themistokles

Chamogeorgakis, MD

Not pictured: Brian Lima, MD; Amarinda Bindra,

MD; Parag Kale, MD; Adnan Khalid, MD; Jose

Mendez, MD

Abdominal Transplant Surgery Team L to R: Peter Kim, MD; Nicholas Onaca, MD; Tiffany

Anthony, MD; Robert M. Goldstein, MD, FACS; Richard

Ruiz, MD, FACS; Göran B. Klintmalm, MD, PhD, FACS;

Gregory J. McKenna, MD; Giuliano Testa, MD, FACS,

MBA; Marlon F. Levy, MD, FACS

Lung Team Kenneth Ausloos, MD; David Mason, MD;

Alexis Shafii, MD; Randall Rosenblatt, MD;

Howard Huang, MD

Not pictured: Themistokles Chamogeorgakis, MD;

Aldo Rafael, MD

35

MEDICAL STAFF

36

NORTH TEXAS’ FIRST islet cell transplant

NATION’S FIRST certified VAD program

SOUTHWEST’S FIRST adult liver transplant

WORLD’S FIRST extra-corporeal perfusion (bridge

to transplant) using a genetically engineered pig

liver, keeping the patient alive before successfully

undergoing liver transplantation

NORTH TEXAS’ FIRST split-liver procedure:

a donor liver was divided into two lobes for a

pediatric and an adult recipient

NORTH TEXAS’ FIRST adult-to-adult living donor

liver transplant procedure

NORTH TEXAS’ FIRST heart/lung/heart “domino”

procedure: a patient with terminal emphysema

received a heart and two lungs, while a patient with

cardiomyopathy received the good heart from the

emphysema patient

NORTH TEXAS’ FIRST paired kidney

donor transplant

NORTH TEXAS’ FIRST and only living liver

donor program

BAYLOR

FIRSTSTRANSPLANTSMAKE L IFEWORTH LIVING

We receive countless comments from our

family of more than 11,000 patients about

life after transplant. Comments such as:

“Thanks to the liver I received, I was

able to pass my knowledge to a new

generation of physicists.”

“I married my beautiful wife, and a few

years later we adopted our son.”

“I had to put school on hold while

my chronic kidney disease progressed.

I graduated with my MBA this past

Friday!”

“Dancing with my daughter was a

pleasure we would not have had without

a donor and willing family, the Baylor

transplant team and the grace of God.”

For all the milestones our transplant program

has achieved, the greatest are those celebrated

by our patients. Their stories remind us

that as transplantation changes lives it

changes history. After 30 years of pioneering

transplants, we are honored to reflect on the

miracles in generations of lives that our work

has made possible.

36

Cancer research studies on the campus of Baylor University Medical Center at Dallas and Baylor All Saints Medical Center at Fort Worth are conducted through Baylor Research Institute, Texas Oncology and US Oncology. Each reviews, approves and conducts clinical trials independently. Their clinical trials are listed together in this publication for the convenience of patients and physicians.

Physicians provide clinical services as members of the medical staff at one of Baylor Scott & White Health’s subsidiary, community or affiliated medical centers and do not provide clinical services as employees or agents of those medical centers, Baylor Health Care System, Scott & White Healthcare or Baylor Scott & White Health. Individual results may vary. Not all services available at all locations. ©2015 Baylor Scott & White Health.

For our patients—who continually

amaze us with their perseverance.

For our donors—who gave the

ultimate gift, the possibility of life.

For our physicians and staff—who

help make it all happen.

Baylor Annette C. and Harold C. Simmons Transplant Institute is the integration of transplant services at Baylor University Medical Center at Dallas and Baylor All Saints Medical Center at Fort Worth. Together, Baylor Dallas and Baylor Fort Worth are one of the largest multispecialty transplant centers in the country.

1.800.774.2487 BaylorHealth.com/Transplant